The daily costs of chemotherapy-associated adverse events: A cluster-based analysis

Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning†

“…Although we found no difference in time to myeloid engraftment in the treated UCB group when compared with untreated UCB recipients, our study was not randomized and included a relatively small number of patients. Based on the daily cost of $1704 for hospitalization for neutropenia alone (48), even a minor reduction in days to myeloid engraftment might lead to significant cost‐savings and provide support for HGF use in pediatric UCB patients post‐MA‐alloSCT. A pharmacoeconomic study comparing delay in myeloid recovery to cost of HGF administration and cost of daily hospitalization in both a treatment and control group would have to be performed to determine this benefit.…”